

• For patients who report behavior that places them at risk for HIV acquisition, a negative HIV test result is an opportunity to encourage PrEP use. When used as prescribed, PrEP effectively prevents HIV acquisition.

• TDF/FTC is the preferred PrEP regimen during pregnancy and while breastfeeding. When indicated, PrEP is an effective component of a comprehensive HIV prevention plan that includes counseling and education about adherence to PrEP medications, ongoing monitoring with laboratory testing, and discussion of risk-reduction strategies. For more information regarding PrEP, see the NYSDOH AI guideline *PrEP to Prevent HIV and Promote Sexual Health*.

Universal Hepatitis C Virus (HCV) Screening

• The NYSDOH AI currently recommends universal HCV screening during each pregnancy. See the NYSDOH AI guideline *Treatment of Chronic Hepatitis C Virus Infection in Adults > HCV Testing and Management in Pregnant Adults*.

Routine STI HIV Screening in Pregnancy

• Routine screening for chlamydia, gonorrhea, and syphilis can be combined with HIV testing at the initial visit and at 28 to 32 weeks gestation.

• This committee encourages healthcare providers to recommend HIV testing for sex partner(s) of pregnant patients. During the first prenatal visit, when the clinician provides counseling about HIV and other health conditions, the care provider can suggest that a patient's sex partner(s) undergo testing for HIV. The same suggestion can be made if a patient is diagnosed with a new STI or reports having new sex partners during pregnancy. Whenever possible, the clinician should offer direct linkage to HIV testing and prevention services for partners.

Reactive HIV Test Result During Labor

• If the result of the expedited HIV test for a patient in labor is reactive:

- Discuss the meaning of a preliminary positive HIV test result.
- Do not delay prophylaxis while awaiting results of confirmatory serologic testing. Inform the birth parent that HIV can be transmitted through breast milk and that breastfeeding is contraindicated until they are confirmed to be HIV negative. Refer the birth parent to a lactation specialist to assist with education and support for maintenance of breast milk supply, if so desired, so breastfeeding may be initiated if HIV infection is excluded.
- Provide education about the benefits of antiretroviral prophylaxis for any patient with HIV who declines it for themselves or their newborn.

8 → SELECTED GOOD PRACTICE REMINDERS AND KEY POINTS

8 → SELECTED GOOD PRACTICE REMINDERS AND KEY POINTS (continued)

PrEP continued

- Repeat screening for HIV and other STIs (chlamydia, gonorrhea, and syphilis) is part of routine PrEP management. See the CDC 2021 *STI Treatment Guidelines*.
- The use of ARV medications during pregnancy is monitored through the Antiretroviral Pregnancy Registry.

HIV Testing During Labor and in Newborns

- Maternal HIV acquisition and acute infection confer a significant risk of HIV transmission to an infant who is being breastfed.
- The peripartum period is the final opportunity to provide ARV prophylaxis and decrease the risk for perinatal HIV transmission to exposed infants of individuals who have not been previously identified as having HIV.
- As in the prenatal and peripartum periods, when a breastfeeding patient presents with symptoms suggestive of acute HIV infection, the clinician should perform an HIV test in conjunction with a plasma HIV RNA test immediately, even if previous HIV screening tests were nonreactive.
- Providing information about HIV and recommending HIV testing as early as possible in pregnancy is ideal.



← Use this code with your phone's QR code reader to go directly to a mobile-friendly version of the guideline.

■ This 1/4-Folded Guide is a companion to the New York State Department of Health AIDS Institute guideline *HIV Testing During Pregnancy, at Delivery, and Postpartum*. The full guideline is available at www.hivguidelines.org.

ALL RECOMMENDATIONS (continued from P.1)

P.2

Third Trimester HIV and Syphilis Testing continued

- Clinicians should repeat HIV testing in all pregnant patients who have engaged in behaviors that put them at risk of HIV acquisition during pregnancy or have acquired other STIs. (A2)
- Clinicians should repeat syphilis testing along with HIV testing in the third trimester in all pregnant patients. (A2)

PrEP to Prevent HIV

- If a patient with a negative HIV test result requests PrEP or reports being at risk of HIV acquisition, clinicians should provide or promptly refer the patient for PrEP services. (A1) PrEP with TDF/FTC is not contraindicated during pregnancy or while breastfeeding an infant.
- When a patient in labor is not known to have HIV, does not have a documented third-trimester negative HIV test result, has been diagnosed with an STI during pregnancy, or reports exposure to sex partners, the clinician should perform expedited HIV testing with consent and discuss the use of antiretroviral prophylaxis for the patient and the newborn. (A2)
- If the result of the expedited HIV screening test for a patient in labor is reactive, the clinician should:
 - Obtain HIV diagnostic testing according to the standard HIV laboratory testing algorithm. (A1)
 - Initiate maternal ARV prophylaxis (A1); immediate initiation is recommended. (A2)
 - Administer newborn prophylaxis as soon as possible after birth. (A2)
 - If supplemental diagnostic testing confirms that a patient in labor has HIV, the clinician should:
 - Ensure that an HIV diagnostic test of the infant has been obtained within 48 hours of birth. The infant's specimen should be sent to the Pediatric HIV Testing Service at the Wadsworth Center for a nucleic acid test to detect HIV-1 RNA or DNA. (B3)
 - Make arrangements for the patient with newly diagnosed HIV to see an experienced HIV care provider and, if indicated, provide referrals for case management and support services. (A3)
 - Ensure that the HIV-exposed infant is discharged from care with antiretroviral medications in hand, not just a prescription. (B3)
 - Make arrangements for the infant's medical follow-up with an experienced pediatric HIV care provider. (A3)

HIV CLINICAL RESOURCE ■ 1/4-FOLDED GUIDE
VISIT HIVGUIDELINES.ORG TO LEARN MORE OR VIEW COMPLETE GUIDE

HIV TESTING DURING PREGNANCY, AT DELIVERY, AND POSTPARTUM
NYSDOH AIDS INSTITUTE HIV CLINICAL GUIDELINE SEPTEMBER 2022

ALL RECOMMENDATIONS **P.1**

Universal Screening in Pregnancy

- Using an FDA-approved HIV-1/2 Ag/Ab combination immunoassay and following the standard HIV laboratory testing algorithm, clinicians should screen all patients early in pregnancy, regardless of reported exposure, risk, or symptoms. (A2)
- Clinicians should refer patients who test positive for HIV to an experienced HIV care provider who can manage antiretroviral therapy (ART) initiation (ideally within 3 days). (A3)

Testing for Acute HIV

- When a patient presents with symptoms suggestive of acute HIV infection, the clinician should perform an HIV test immediately, even if a previous HIV screening test result during the current pregnancy was nonreactive. (A2)
- Clinicians should maintain a high level of suspicion for acute HIV in all pregnant patients who present with a compatible clinical syndrome. (A3)
- When screening for acute HIV, clinicians should obtain plasma HIV RNA testing in conjunction with HIV serologic testing, preferably with a an HIV-1/2 Ag/Ab combination immunoassay; the plasma HIV RNA test should be performed even if the HIV serologic screening test result is nonreactive or indeterminate. (A2)
- If a patient's plasma HIV RNA test result indicates a viral load $\geq 5,000$ copies/mL (or ≥ 200 copies/mL for patients taking PrEP or PEP), the clinician should make a presumptive diagnosis of acute HIV, even if the results of screening and HIV-1/HIV-2 Ab differentiation immunoassays are nonreactive or indeterminate. (A2)
- If a patient's viral load is detectable but lower than the levels stated above, to rule out acute HIV infection, the clinician should repeat the plasma HIV RNA test 2 weeks after the first test, preferably with a repeat HIV-1/2 Ag/Ab combination immunoassay. (A3)

Third Trimester HIV and Syphilis Testing

- Before 36 weeks' gestation (preferably between weeks 28 and 32), clinicians should repeat HIV testing for all patients with either a negative HIV test result or no documented HIV test result early in pregnancy. (A2)

Continued on next panel >

Checklist for HIV Testing and Prophylaxis During Labor and in Newborns

From the New York State Department of Health AIDS Institute guideline *HIV Testing During Pregnancy, at Delivery, and Postpartum*.
www.hivguidelines.org. September 2022

□ Repeat HIV Testing

- For patients in labor who do not have documented third-trimester HIV test results, have been diagnosed with a sexually transmitted infection during pregnancy, or report exposure risk for themselves or sex partners, perform expedited HIV testing with consent and discuss the use of antiretroviral (ARV) prophylaxis for the patient and the newborn.

□ Provide Counseling and Education About ARV Prophylaxis

- Counsel regarding the use of ARV prophylaxis in the birth parent and the infant.
- Provide education about the benefits of ARV prophylaxis for any patient with HIV who declines it for themselves or their newborn.

□ Manage a Reactive HIV Screening Test Result

- Obtain HIV diagnostic testing according to the standard HIV laboratory testing algorithm.
- Initiate maternal ARV prophylaxis; immediate initiation is recommended.
- Administer newborn prophylaxis as soon as possible after birth. See U.S. Department of Health and Human Services *Management of Infants Born to People with HIV Infection*.
- Discuss the meaning of a preliminary positive HIV test result.
- Do not delay prophylaxis while awaiting results of confirmatory serologic testing.
- Inform the birth parent that HIV can be transmitted through breast milk and that breastfeeding is not recommended until they are confirmed to be HIV negative.

□ Manage a Confirmed HIV Diagnosis in the Parent

- If supplemental diagnostic testing confirms that a patient in labor has HIV, ensure an HIV diagnostic test of the infant is obtained within 48 hours of birth. Send the infant's specimen to the Pediatric HIV Testing Service at the Wadsworth Center for nucleic acid testing to detect HIV-1 RNA or DNA.
- Make arrangements for the patient with newly diagnosed HIV to see an experienced HIV care provider and, if indicated, provide referrals for case management and support services.
- Ensure that the HIV-exposed infant is discharged from care with ARV medications in hand, not just a prescription.
- Make arrangements for the infant's medical follow-up with an experienced pediatric HIV care provider.

□ Resources

- Wadsworth Center Order Desk to Obtain a Pediatric HIV Test Kit: 518-474-4175
- Clinical Education Initiative (CEI) Line: 866-637-2342
- NYSDOH AI Clinical Guidelines Program: www.hivguidelines.org

NEW YORK STATE LAW

- Clinicians in prenatal care settings must provide HIV-related information and recommend HIV testing for all pregnant patients, including those who present in labor if their HIV status is not documented.
- Immediately arrange an expedited HIV test, with consent, for patients in labor when no HIV test result is documented for the current pregnancy, with results available as soon as possible.
- If a patient who presents in labor declines an HIV test, the infant is required to have an expedited HIV antibody screen at birth, with or without consent, with results available as soon as possible but no later than 12 hours after birth.
- If the infant's HIV test is reactive for HIV antibodies, a plasma sample should be collected from the infant for HIV-1 nucleic acid testing. (See *New York Codes, Rules and Regulations [NYCRR] Title 10, Section 69-1.3*.)
- The hospital shall determine the need for, and ensure provision of, HIV prophylaxis and/or treatment per standard of care to prevent transmission to the infant, and shall record such in both the birth parent's and newborn's health records. (See *NYCRR Title 10, Section 405.21*.)

NEW YORK STATE PUBLIC HEALTH LAW

Partner Notification

- Clinicians must discuss partner notification with patients who have been recently diagnosed with HIV, and the discussion must be documented in the medical record and on the *Medical Provider Reporting Form (DOH-4189)*, as required by *Public Health Law, Article 21, Title 3, Section 2130*.

Universal HIV Screening

- Clinicians in prenatal care settings must provide HIV-related information and recommend HIV testing for all pregnant patients, including those who present in labor if their HIV status is not documented.
- Immediately arrange an expedited HIV test, with consent, for patients in labor when no HIV test result is documented for the current pregnancy, with results available as soon as possible.

HIV Testing

- Any patient who does not have a documented HIV test result during the current pregnancy and who is not known to have HIV must, with their consent, receive expedited HIV testing during labor; results must be available within 12 hours of consent and preferably within 60 minutes. All birth facilities must have the capacity to provide and perform expedited HIV testing.
 - Facilities should use a U.S. Food and Drug Administration-approved HIV screening test, with results available preferably within 1 hour and no longer than 12 hours; the most sensitive screening test available should be used to allow for detection of early or acute HIV.
 - Ensure that expedited HIV test results are available prior to delivery to allow maximum benefits of intrapartum antiretroviral prophylaxis for the fetus.
 - Supplemental diagnostic testing must be obtained for all preliminary positive HIV test results in pregnant patients.
 - If a patient who presents in labor declines an HIV test, the infant is required to have an expedited HIV antibody screen at birth, with or without consent, with results available as soon as possible but no later than 12 hours after birth.
 - If the infant HIV test is reactive for HIV antibodies, a plasma sample should be collected from the infant for HIV-1 nucleic acid testing. See *New York Codes, Rules and Regulations (NYCRR) Title 10, Section 69-1.3*.
 - The *DOH-4068 Maternal-Pediatric HIV Prevention and Care Program Test History and Assessment* form must be completed for every pregnant individual presenting for delivery.

Antiretroviral Prophylaxis

- The hospital shall determine the need for, and ensure provision of, HIV prophylaxis and/or treatment per standard of care to prevent transmission to the infant, and shall record such in both the birth parent's and newborn's health records. (See *NYCRR Title 10, Section 405.21*.)